Vivien Hébert
Vivien Hébert is an expert in Dermatology at Centre Hospitalier Universitaire de Rouen (France). As of September 2026, ScienceLeadR ranks Vivien Hébert in the top 1% of experts worldwide for Skin Diseases, Vesiculobullous. Vivien Hébert has authored 108 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 4 of them ongoing. SLR score: 447 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Immunology - Public Health - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2017 - 2026
Number : 108
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis. PMID 42390708 — safety, rituximab, therapeutics, pemphigus | Dermatol Ther (Heidelb) | 2026 | 0 |
| Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus. PMID 42314934 — cells, antibodies, plasma cells, desmogleins, rituximab, therapeutics, pemphigus, dermatology, b-lymphocytes, plasma | J Invest Dermatol | 2026 | 0 |
| Tocilizumab for severe and refractory mucous membrane pemphigoid. PMID 42200380 — cytokines, sexually transmitted diseases, serum, skin diseases, pemphigoid, bullous, proteomics, mucous membrane, membranes | J Eur Acad Dermatol Venereol | 2026 | 0 |
| Incidence and Mortality of Mucous Membrane Pemphigoid in France. PMID 42114084 — mortality, syphilis, incidence, ear, pemphigoid, bullous, nose, mucous membrane, dermatology, membranes | Br J Dermatol | 2026 | 0 |
| French national protocol for diagnosis and management of pemphigoid gestationis. PMID 42025012 — sexually transmitted diseases, pemphigoid gestationis, pemphigoid, bullous, diagnosis, dermatology | Ann Dermatol Venereol | 2026 | 0 |
Clinical Studies 8
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to 12 Years of Age With Severe Alopecia Areata 2024-515438-33-00 — safety, alopecia areata, child, alopecia | Phase 3 | Active not recruiting | 2026 |
| Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris a Prospective Multicenter Randomized Placebo controlled Study NCT07492251 — skin, cells, safety, lichens, therapeutics, penis, lichen planus, wounds and injuries | Phase 2 | Not yet recruiting | 2026 |
| Ustekinumab in BEh et s Syndrome STudy NCT07244614 — ustekinumab, behcet syndrome, pathology, research, records, therapeutics, biosimilar pharmaceuticals | N/A | Recruiting | 2025 |
| Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy NCT05689463 — autoantibodies, serology, serum, immunoglobulins, immunotherapy, pruritus, prevalence | N/A | Recruiting | 2023 |
LeadR Networks
Main global connection map